Company Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.
The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab.
Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Denise Scots-Knight |
Contact Details
Address: One Cavendish Place, 4th Floor London, W1G 0QF United Kingdom | |
| Phone | 44 33 3023 7300 |
| Website | mereobiopharma.com |
Stock Details
| Ticker Symbol | MREO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001719714 |
| CUSIP Number | 589492107 |
| ISIN Number | US5894921072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, Chief Executive Officer and Executive Director |
| Charles Edward Sermon | Co-Founder, General Counsel, Business Development and Company Secretary |
| Christine Fox CPA | Chief Financial Officer |
| Dr. John P. Richard M.B.A. | Co-Founder and Chief Business Officer |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer |
| Dr. Jackie Parkin | Senior Vice President and Therapeutic Head |
| Alexandra Hughes-Wilson | Chief of Patient Access and Commercial Planning |
| Dr. Suba Krishnan | Senior Vice President of Clinical Development |
| Bo Kara | Senior Vice President and Head of Pharmaceutical Development and CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 6, 2024 | SCHEDULE 13G/A | Filing |
| Dec 4, 2024 | EFFECT | Notice of Effectiveness |
| Dec 4, 2024 | 424B3 | Prospectus |
| Nov 25, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |